Gen-M Ds Oral Suspension 30Ml

Name: Gen-M Ds Oral Suspension 30Ml
Brand: GENIX PHARMA PRIVATE LIMITED
Price: 300.2

Brand : genix pharma private limited

Rs. 300.20

Rs. 316.00

|

QUICK DELIVERY

Gen-M Ds Specification

Requires Prescription (YES/NO)

Yes

Generics

Artemether , Lumefantrine

Used For

Malaria

How it works

Both components Artemether/ Lumefantrine have their own action site in the malarial parasite. The presence of the endoperoxide bridge in Artemether (generating single oxygen and free radicals, those are very cytotoxic to the plasmodia) appears to be essential for antimalarial activity.

Gen-M Ds Usage And Safety

Dosage

Artemether , Lumefantrine

Side Effects

Very Common: Palpitations, headache, dizziness, abdominal pain, anorexia, vomiting, nausea, arthralgia, mylagia, asthenia, fatigue, sleep disorders.Common: Amnesia, paraesthesia, diarrhea, pruritus, rash, cough, electrocardiogram QT prolongation, gait disturbances, insomia.Uncommon: Liver function test increased, clonus, hypoesthesia, ataxia, somnolence.

Drug Interactions

CYP3A4 inhibitors (e.g. erythromycin, ketoconazole, itraconazole, cimetidine, HIV protease inhibitors, etc.) , CYP2D6 inhibitors (e.g. flecainide, metoprolol, imipramine, amitryptyline, clomipramine, etc.) , Mefloquine.

Indication

Used in the treatment of Malaria.

When not to Use

It is contraindicated to those patients which have a history of hypersensitivity to Artemether / Lumefantrine.

Gen-M Ds Precautions

Precaution

Due to limited data on safety and efficacy, Artemether+Lumefantrine should not be given concurrently with any other anti-malarial agent unless there is no other treatment option.

Gen-M Ds Warnings

Warning 1

Caution is advised when administering Artemether + Lumefantrine to patients with severe renal, hepatic or cardiac problems. In such cases, monitoring of the ECG is recommended and steps should be taken to correct any electrolyte disturbances.

Warning 2

Caution is recommended when combining Artemether + Lumefantrine with drugs exhibiting variable patterns of inhibition, induction or competition for CYP3A4 as the therapeutic effects of some drugs could be altered.

Warning 3

Patients who remain averse to food during treatment should be closely monitored as the risk of recrudescence may be greater.